Therapeutic Areas
Therapeutic Areas
The LoxiGen, Inc. seeks excellence in science, with a vision to develop the best-in-class innovative therapeutics. Our portfolio includes several key therapeutic areas, including cancer, fibrosis, and cardiac diseases where the dysregulation of lysyl oxidase family members has profound impact and benefits of lysyl oxidase inhibition have been proven. The lysyl oxidase family proteins are copper-dependent enzymes, mediating the conversion of lysine residues in collagen and elastin precursors into highly reactive aldehydes. Thereby, they trigger crosslinking and stabilization of extracellular matrix (ECM) proteins, leading to ECM organization which is known to be deregulated in different diseases, including cancer and fibrosis-related diseases.
Figure Describing TACC3 and Its Interactors
A highly potent, orally bioavailable TACC3 inhibitor (OC-02) with high efficacy and minimum toxicity was developed. This initial molecule was further developed by the OncoCube&A2A Collaborative Drug Development Program and the optimized lead molecule, AO-252 obtained the Investigational New Drug (IND) designation from the U. S. Food and Drug Administration (FDA) on May 22, 2023 to begin a Phase I study in adult patients with HGSOC, TNBC and endometrial cancers.
1. PLoS Genet. 2015 Jul 2;11(7):e1005345. doi: 10.1371/journal.pgen.1005345.
2. EMBO J. 2011 Mar 2;30(5):906-19. doi: 10.1038/emboj.2011.15.
3. Cancer Cell 2017 Oct 9;32(4):444-459.e7. doi: 10.1016/j.ccell.2017.09.002.
4. Cell Death Differ. 2023 May;30(5):1305-1319. doi: 10.1038/s41418-023-01140-1.
5. J Cell Sci. 2021 Feb 1;134(3):jcs255794. doi: 10.1242/jcs.255794.
6. Proc Natl Acad Sci U S A. 2011 May 10;108(19):7739-44. doi: 10.1073/pnas.1101357108.
7-Nucleic Acids Res. 2006 Jan 12;34(1):364-72. doi: 10.1093/nar/gkj400. Print 2006.
2. EMBO J. 2011 Mar 2;30(5):906-19. doi: 10.1038/emboj.2011.15.
3. Cancer Cell 2017 Oct 9;32(4):444-459.e7. doi: 10.1016/j.ccell.2017.09.002.
4. Cell Death Differ. 2023 May;30(5):1305-1319. doi: 10.1038/s41418-023-01140-1.
5. J Cell Sci. 2021 Feb 1;134(3):jcs255794. doi: 10.1242/jcs.255794.
6. Proc Natl Acad Sci U S A. 2011 May 10;108(19):7739-44. doi: 10.1073/pnas.1101357108.
7-Nucleic Acids Res. 2006 Jan 12;34(1):364-72. doi: 10.1093/nar/gkj400. Print 2006.
Cupidatat non proident sunt in culpa qui officia deserunt est laborum
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.
1. PLoS Genet. 2015 Jul 2;11(7):e1005345. doi: 10.1371/journal.pgen.1005345.
2. EMBO J. 2011 Mar 2;30(5):906-19. doi: 10.1038/emboj.2011.15.
3. Cancer Cell 2017 Oct 9;32(4):444-459.e7. doi: 10.1016/j.ccell.2017.09.002.
4. Cell Death Differ. 2023 May;30(5):1305-1319. doi: 10.1038/s41418-023-01140-1.
5. J Cell Sci. 2021 Feb 1;134(3):jcs255794. doi: 10.1242/jcs.255794.
6. Proc Natl Acad Sci U S A. 2011 May 10;108(19):7739-44. doi: 10.1073/pnas.1101357108.
7-Nucleic Acids Res. 2006 Jan 12;34(1):364-72. doi: 10.1093/nar/gkj400. Print 2006.
